Telmisartan and Rosuvastatin Tablets 80/20 mg
Telmisartan 80mg · Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication · Combination
Myungmoon Pharmaceutical Co., Ltd.
MFDS item code 202001846 · Approved 2020.03.17
This product's status changed to Expired on 2025.10.31. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of hypertension; improvement of dyslipidemia; reduction of cardiovascular disease risk and inhibition of atherosclerosis progression
This medicine is used for patients who need to take both telmisartan and rosuvastatin at the same time. Telmisartan is effective in treating essential hypertension and lowering the risk of cardiovascular disease. It particularly helps in reducing the risk of myocardial infarction, stroke, and related deaths in high-risk patients aged 55 and older. Rosuvastatin improves dyslipidemia such as hypercholesterolemia, slows the progression of atherosclerosis, and reduces the risk of cardiovascular diseases, strokes, and myocardial infarctions. These two medications are used to improve cardiovascular health by controlling both blood pressure and blood lipid levels in patients at high risk for cardiovascular diseases.
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each ingredient, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg orally once daily as telmisartan; depending on the patient, 20 mg once daily may be effective. If necessary, the dose may be increased to 80 mg once daily. This medicine has an additional blood pressure-lowering effect when administered concomitantly with thiazide diuretics such as hydrochlorothiazide. When the dose is increased, the maximum blood pressure-lowering effect is generally achieved 4 ∼ 8 weeks after starting treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg is not known. When initiating treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be necessary. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and patient response; the dose may be increased to a maximum of 20 milligrams daily. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. For patients taking telmisartan and rosuvastatin concomitantly, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.
This medication can cause serious harm to the fetus if taken during pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. Pregnant or potentially pregnant women and nursing mothers should not use this medication, and women of childbearing age should use appropriate contraception. It is not safe to administer this medication to patients with severely impaired liver function or those with biliary obstruction. Patients with a history of muscle-related diseases or genetic myopathies are at risk for muscle damage when taking this medication, so caution is needed. Patients with severely impaired renal function should also avoid this medication, and its co-administration with certain immunosuppressants is prohibited. Caution is required when prescribing this medication to the elderly, patients with hyperkalemia, and patients with slightly impaired liver function; regular monitoring of liver enzymes and blood potassium levels should be conducted. This medication may cause side effects such as muscle pain, myopathy, abnormal liver function, gastrointestinal symptoms, headache, and dizziness, and if any unusual symptoms occur, consulting a physician immediately is advised. In particular, if unexplained muscle pain or weakness occurs, immediate testing should be pursued, and if necessary, the medication should be discontinued. This medication may interact with others, so any other medications being taken should be communicated to healthcare providers. Caution is needed when driving or operating machinery due to potential dizziness or drowsiness. Store this medication out of reach of children and avoid transferring it to other containers.
Headache, postural dizziness, sleep paralysis, increased blood pressure, decreased blood pressure, hypotension, elevated ALT, dysuria, rhinitis, pharyngeal discomfort, pulmonary disease, unspecified gastrointestinal disease, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory loss, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, halitosis, fatty liver, upper respiratory infection, urinary tract infection, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reaction, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, syncope, visual disturbances, dizziness, bradycardia, tachycardia, dyspnea, abdominal pain, diarrhea, dyspepsia, abdominal bloating, vomiting, abdominal discomfort, dry mouth, liver function abnormalities, hepatic impairment, increased sweating, pruritus, rash, erythema, angioedema, drug rash, toxic skin rash, eczema, urticaria, myalgia, back pain, muscle cramps, arthralgia, limb pain, tendinopathy, acute renal failure, chest pain, weakness, influenza-like illness, increased serum creatinine, increased serum uric acid, elevated liver enzymes, increased serum CK, decreased hemoglobin, liver dysfunction, jaundice, symptoms resembling anaphylaxis, interstitial pneumonia, rhabdomyolysis, palpitations, fatigue, nausea, lack of efficacy, facial spasms, sensory abnormalities, paralysis, hyperventilation, pneumonia, flushing, erectile dysfunction, loss of appetite, arrhythmia, weakness, edema, decreased libido, facial swelling, alopecia, conjunctivitis, tinnitus, petechiae, headache, dizziness, constipation, nausea, pancreatitis, pruritus, rash, urticaria, myopathy, immune-mediated necrotizing myopathy, weakness, peripheral neuropathy, diarrhea, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, arthralgia, hematuria, edema, depression, sleep disorders, sexual dysfunction, gynecomastia, fatal and non-fatal hepatic failure, cognitive impairment, severe muscle weakness, ocular myasthenia, myalgia, elevated CK, arthralgia, numbness, sensory abnormalities, chest discomfort, loss of appetite, abdominal bloating, syncope, generalized pain, muscle cramps, gout
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and humidity, so it should be stored in a tightly sealed container. The recommended storage temperature is between 1 and 30 degrees Celsius at room temperature. This will help maintain the effectiveness of the medication over time.
White oval film-coated tablets
30 tablets/box [(10 tablets/PTP*3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Telmisartan 80mg · Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication · Combination
Myungmoon Pharmaceutical Co., Ltd.
CombinationTelmisartan 80mg · Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication · Combination
Yuhan Corporation.
CombinationTelmisartan 40mg · Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication · Combination
Yuhan Corporation
CombinationTelmisartan 80mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Yuhannanghang Co., Ltd.
CombinationTelmisartan 40mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Yuhan Corporation Co., Ltd.
CombinationTelmisartan 40mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Yuhan Corporation
CombinationTelmisartan 80mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Yuhan Corporation
CombinationTelmisartan 40mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Ildong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.